(Q37230695)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

title

Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

neoadjuvant chemotherapy

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

Ana Maria Gonzalez-Angulo

11 January 2020

6

object named as

A M Gonzalez-Angulo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

2

A U Buzdar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

F Peintinger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

H M Kuerer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

J A Mejia

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

L Pusztai

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

F J Esteva

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

S S Dawood

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

M C Green

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

G N Hortobagyi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

W F Symmans

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

publication date

29 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

page(s)

2020-2025

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

11 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2733116

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2733116

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2733116

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2733116

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2733116

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2733116

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2733116

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2733116

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2733116

Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2733116

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2733116

Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18667396

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/ANNONC/MDN427

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18667396%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference